KR20220167324A - 단백질 응집 장애의 치료를 위한 조성물 및 방법 - Google Patents
단백질 응집 장애의 치료를 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20220167324A KR20220167324A KR1020227039402A KR20227039402A KR20220167324A KR 20220167324 A KR20220167324 A KR 20220167324A KR 1020227039402 A KR1020227039402 A KR 1020227039402A KR 20227039402 A KR20227039402 A KR 20227039402A KR 20220167324 A KR20220167324 A KR 20220167324A
- Authority
- KR
- South Korea
- Prior art keywords
- fusion protein
- protein
- polyglutamine
- sequence
- dnaj
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008251P | 2020-04-10 | 2020-04-10 | |
| US63/008,251 | 2020-04-10 | ||
| PCT/US2021/026633 WO2021207636A2 (en) | 2020-04-10 | 2021-04-09 | Compositions and methods for the treatment of protein aggregation disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220167324A true KR20220167324A (ko) | 2022-12-20 |
Family
ID=75747121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227039402A Pending KR20220167324A (ko) | 2020-04-10 | 2021-04-09 | 단백질 응집 장애의 치료를 위한 조성물 및 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230226223A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4132955A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023520927A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220167324A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115667289A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021254272A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022020444A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012525A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202204383A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021207636A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114057858B (zh) | 2020-08-10 | 2023-03-21 | 上海瑞吉康生物医药有限公司 | 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽 |
| AU2021367952A1 (en) * | 2020-10-26 | 2023-06-08 | Sola Biosciences Llc | Compositions and methods for the treatment of alzheimer's disease |
| EP4686478A1 (en) * | 2024-07-31 | 2026-02-04 | Consejo Superior de Investigaciones Científicas (CSIC) | Qbp1 for use in the treatment and/or prevention of type 2 diabetes |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| EP1002119A1 (en) | 1997-07-31 | 2000-05-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| DE69939169D1 (de) | 1998-05-28 | 2008-09-04 | Us Gov Health & Human Serv | Aav5 vektoren und deren verwendung |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| JP2008125455A (ja) * | 2006-11-22 | 2008-06-05 | Sapporo Medical Univ | ポリグルタミン凝集体形成阻害活性を有するポリペプチド |
| US20100016221A1 (en) * | 2008-07-17 | 2010-01-21 | Riken | Method of degrading protein by chaperone-mediated autophagy |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| US9169494B2 (en) | 2010-01-12 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| WO2011097456A2 (en) | 2010-02-05 | 2011-08-11 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
| WO2011140315A2 (en) * | 2010-05-05 | 2011-11-10 | Northwestern University | Method of reducing proteins misfolding and/or aggregation |
| WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| EP2929045B1 (en) * | 2012-12-05 | 2020-12-02 | SOLA Biosciences LLC | Protein expression enhancing polypeptides |
| WO2018058088A1 (en) * | 2016-09-26 | 2018-03-29 | SOLA Biosciences, LLC | Cell-associated secretion-enhancing fusion proteins |
-
2021
- 2021-04-09 JP JP2022561477A patent/JP2023520927A/ja active Pending
- 2021-04-09 EP EP21722705.7A patent/EP4132955A2/en active Pending
- 2021-04-09 MX MX2022012525A patent/MX2022012525A/es unknown
- 2021-04-09 AU AU2021254272A patent/AU2021254272A1/en active Pending
- 2021-04-09 CN CN202180041478.7A patent/CN115667289A/zh active Pending
- 2021-04-09 WO PCT/US2021/026633 patent/WO2021207636A2/en not_active Ceased
- 2021-04-09 TW TW110112984A patent/TW202204383A/zh unknown
- 2021-04-09 BR BR112022020444A patent/BR112022020444A2/pt unknown
- 2021-04-09 US US17/995,901 patent/US20230226223A1/en active Pending
- 2021-04-09 KR KR1020227039402A patent/KR20220167324A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115667289A (zh) | 2023-01-31 |
| MX2022012525A (es) | 2023-02-22 |
| JP2023520927A (ja) | 2023-05-22 |
| WO2021207636A3 (en) | 2021-11-18 |
| BR112022020444A2 (pt) | 2022-11-29 |
| WO2021207636A2 (en) | 2021-10-14 |
| US20230226223A1 (en) | 2023-07-20 |
| AU2021254272A1 (en) | 2022-10-27 |
| TW202204383A (zh) | 2022-02-01 |
| EP4132955A2 (en) | 2023-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100422320C (zh) | 编码抗肌萎缩蛋白小基因的dna序列及其使用方法 | |
| US20240327477A1 (en) | Compositions and methods for the treatment of tdp-43 proteinopathies | |
| KR102537394B1 (ko) | 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법 | |
| EP3292138B1 (en) | Production of large-sized microdystrophins in an aav-based vector configuration | |
| US20230234997A1 (en) | Compositions and Methods for the Treatment of Synucleinopathies | |
| US20230226223A1 (en) | Compositions and Methods for the Treatment of Protein Aggregation Disorders | |
| KR20210132109A (ko) | Dna-결합 도메인 전사활성화제 및 이의 용도 | |
| US20240400626A1 (en) | Compositions and methods for the treatment of p53-mediated cancers | |
| CA3130196A1 (en) | Production of large-sized quasidystrophins using overlapping aav vectors | |
| RU2851326C1 (ru) | Композиции и способы лечения нарушений агрегации белков | |
| KR20250156211A (ko) | 글루코실세라미다제 베타 1 결핍증과 관련된 신경 장애의 치료를 위한 조성물 및 방법 | |
| RU2855933C1 (ru) | Композиции и способы для лечения протеинопатий tdp-43 | |
| US20250042958A1 (en) | Compositions and methods for the treatment of proteopathies | |
| HK40087812A (en) | Compositions and methods for the treatment of protein aggregation disorders | |
| US20240025954A1 (en) | Compositions and Methods for the Treatment of Alzheimer's Disease | |
| HK40088984A (en) | Compositions and methods for the treatment of tdp-43 proteinopathies | |
| HK40092059A (en) | Compositions and methods for the treatment of synucleinopathies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |